The North America T-Cell therapy Market would witness market growth of 16.1% CAGR during the forecast period (2023-2030).
T-cell therapy, sometimes called adoptive cell transfer therapy, is a cutting-edge and individualized type of immunotherapy that uses a patient's natural immune system to target and eradicate cancer cells or other disorders. It entails taking T-cells, a white blood cell, out of the patient's body and altering them in a lab so they can better recognize and kill disease targets or cancer cells. The patient's body is then reinfused with a significant amount of these enlarged, modified T-cells. T-cell therapy provides a potentially efficient and accurate therapeutic alternative by assisting in the immune response's augmentation against the targeted disease.
The primary factors driving the expansion of the market are the rise in cancer prevalence, the aging population, and the increasing usage of multiple-cell therapy approaches for alleviating the symptoms of cancer. Cancers like leukemia, lymphoma, cancer relapse, and myeloma are among those on the rise, raising the need for efficient treatments. In order to make sure that their social and health systems are prepared to capitalize on this demographic transformation, all nations face significant hurdles.
The high demand for the product in this region has been largely ascribed to the region's robust research, commercial basis, and the significant number of clinical trials being conducted for T-cell treatments. The adoption of these therapies has also been hastened, leading to significant market growth due to the rising number of approvals from regulators in Canada and the US, as well as the region's shifting reimbursement environment. Additionally, the rising prevalence of chronic illnesses like cancer and autoimmune diseases and the presence of well-established and powerful market competitors are the main factors for intensive R&D in this region. Thus, the market in North America is anticipated to grow throughout the forecast period due to an increase in cancer incidence and the expansion of clinical trials in T-Cell therapies.
The US market dominated the North America T-Cell therapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $2,375.5 million by 2030. The Canada market is poised to grow at a CAGR of 18.8% during (2023 - 2030). Additionally, The Mexico market would witness a CAGR of 17.7% during (2023 - 2030).
Based on End User, the market is segmented into Hospitals and Cancer Treatment Centers. Based on Indication, the market is segmented into Lymphoma, Acute Lymphocytic Leukemia and Others. Based on Therapy Type, the market is segmented into CAR T-Cell Therapy (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel and Others) and T-Cell Receptor (TCR)-Based. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide T-Cell therapy Market is Projected to reach USD 9.2 Billion by 2030, at a CAGR of 17.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Johnson & Johnson, AbbVie, Inc., Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Sorrento Therapeutics, Inc., Bristol Myers Squibb Company, Immunocore Holdings plc and Pfizer, Inc.
Scope of the Study
Market Segments Covered in the Report:
By End User
- Hospitals
- Cancer Treatment Centers
By Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Others
By Therapy Type
- CAR T-Cell Therapy
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Others
- T-Cell Receptor (TCR)-Based
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Merck KGaA
- Johnson & Johnson
- AbbVie, Inc.
- Gilead Sciences, Inc.
- Amgen, Inc.
- Novartis AG
- Sorrento Therapeutics, Inc.
- Bristol Myers Squibb Company
- Immunocore Holdings plc
- Pfizer, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America T-Cell therapy Market, by End User
1.4.2 North America T-Cell therapy Market, by Indication
1.4.3 North America T-Cell therapy Market, by Therapy Type
1.4.4 North America T-Cell therapy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.2.5 Trials and Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Sep – 2023, May) Leading Players
Chapter 4. North America T-Cell therapy Market by End User
4.1 North America Hospitals Market by Country
4.2 North America Cancer Treatment Centers Market by Country
Chapter 5. North America T-Cell therapy Market by Indication
5.1 North America Lymphoma Market by Country
5.2 North America Acute Lymphocytic Leukemia Market by Country
5.3 North America Others Market by Country
Chapter 6. North America T-Cell therapy Market by Therapy Type
6.1 North America CAR T-Cell Therapy Market by Country
6.2 North America T-Cell therapy Market by CAR T-Cell Therapy Type
6.2.1 North America Axicabtagene Ciloleucel Market by Country
6.2.2 North America Tisagenlecleucel Market by Country
6.2.3 North America Brexucabtagene Autoleucel Market by Country
6.2.4 North America Others Market by Country
6.3 North America T-Cell Receptor (TCR)-Based Market by Country
Chapter 7. North America T-Cell therapy Market by Country
7.1 US T-Cell therapy Market
7.1.1 US T-Cell therapy Market by End User
7.1.2 US T-Cell therapy Market by Indication
7.1.3 US T-Cell therapy Market by Therapy Type
7.1.3.1 US T-Cell therapy Market by CAR T-Cell Therapy Type
7.2 Canada T-Cell therapy Market
7.2.1 Canada T-Cell therapy Market by End User
7.2.2 Canada T-Cell therapy Market by Indication
7.2.3 Canada T-Cell therapy Market by Therapy Type
7.2.3.1 Canada T-Cell therapy Market by CAR T-Cell Therapy Type
7.3 Mexico T-Cell therapy Market
7.3.1 Mexico T-Cell therapy Market by End User
7.3.2 Mexico T-Cell therapy Market by Indication
7.3.3 Mexico T-Cell therapy Market by Therapy Type
7.3.3.1 Mexico T-Cell therapy Market by CAR T-Cell Therapy Type
7.4 Rest of North America T-Cell therapy Market
7.4.1 Rest of North America T-Cell therapy Market by End User
7.4.2 Rest of North America T-Cell therapy Market by Indication
7.4.3 Rest of North America T-Cell therapy Market by Therapy Type
7.4.3.1 Rest of North America T-Cell therapy Market by CAR T-Cell Therapy Type
Chapter 8. Company Profiles
8.1 Merck KGaA
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Johnson & Johnson
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental &Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.3 AbbVie, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Gilead Sciences, Inc.
8.4.1 Company overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expenses
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.4.4.2 Acquisition and Mergers:
8.4.4.3 Trials and Approvals:
8.5 Amgen, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Novartis AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Product Launches and Product Expansions:
8.6.5.2 Acquisition and Mergers:
8.6.5.3 Trials and Approvals:
8.7 Sorrento Therapeutics, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.7.5.2 Trials and Approvals:
8.8 Bristol Myers Squibb Company
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.8.5.2 Acquisition and Mergers:
8.8.5.3 Geographical Expansions:
8.8.5.4 Trials and Approvals:
8.9 Pfizer, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional & Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.5.2 Acquisition and Mergers:
8.10. Immunocore Holdings plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
8.10.4.2 Trials and Approvals:
TABLE 1 North America T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 2 North America T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– T-Cell therapy Market
TABLE 4 Product Launches And Product Expansions– T-Cell therapy Market
TABLE 5 Acquisition and Mergers– T-Cell therapy Market
TABLE 6 Geographical Expansions – T-Cell therapy Market
TABLE 7 Trials and Approvals – T-Cell therapy Market
TABLE 8 North America T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 9 North America T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 10 North America Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 11 North America Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 12 North America Cancer Treatment Centers Market by Country, 2019 - 2022, USD Million
TABLE 13 North America Cancer Treatment Centers Market by Country, 2023 - 2030, USD Million
TABLE 14 North America T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 15 North America T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 16 North America Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 17 North America Lymphoma Market by Country, 2023 - 2030, USD Million
TABLE 18 North America Acute Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 19 North America Acute Lymphocytic Leukemia Market by Country, 2023 - 2030, USD Million
TABLE 20 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 21 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 22 North America T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 23 North America T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 24 North America CAR T-Cell Therapy Market by Country, 2019 - 2022, USD Million
TABLE 25 North America CAR T-Cell Therapy Market by Country, 2023 - 2030, USD Million
TABLE 26 North America T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 27 North America T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 28 North America Axicabtagene Ciloleucel Market by Country, 2019 - 2022, USD Million
TABLE 29 North America Axicabtagene Ciloleucel Market by Country, 2023 - 2030, USD Million
TABLE 30 North America Tisagenlecleucel Market by Country, 2019 - 2022, USD Million
TABLE 31 North America Tisagenlecleucel Market by Country, 2023 - 2030, USD Million
TABLE 32 North America Brexucabtagene Autoleucel Market by Country, 2019 - 2022, USD Million
TABLE 33 North America Brexucabtagene Autoleucel Market by Country, 2023 - 2030, USD Million
TABLE 34 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 35 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 36 North America T-Cell Receptor (TCR)-Based Market by Country, 2019 - 2022, USD Million
TABLE 37 North America T-Cell Receptor (TCR)-Based Market by Country, 2023 - 2030, USD Million
TABLE 38 North America T-Cell therapy Market by Country, 2019 - 2022, USD Million
TABLE 39 North America T-Cell therapy Market by Country, 2023 - 2030, USD Million
TABLE 40 US T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 41 US T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 42 US T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 43 US T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 44 US T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 45 US T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 46 US T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 47 US T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 48 US T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 49 US T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 50 Canada T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 51 Canada T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 52 Canada T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 53 Canada T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 54 Canada T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 55 Canada T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 56 Canada T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 57 Canada T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 58 Canada T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 59 Canada T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 60 Mexico T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 61 Mexico T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 62 Mexico T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 63 Mexico T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 64 Mexico T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 65 Mexico T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 66 Mexico T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 67 Mexico T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 68 Mexico T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 69 Mexico T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 70 Rest of North America T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 71 Rest of North America T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 72 Rest of North America T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 73 Rest of North America T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 74 Rest of North America T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 75 Rest of North America T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 76 Rest of North America T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 77 Rest of North America T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 78 Rest of North America T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 79 Rest of North America T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 80 key Information – Merck KGaA
TABLE 81 Key information –Johnson & Johnson
TABLE 82 Key information – AbbVie, Inc.
TABLE 83 Key Information – Gilead Sciences, Inc.
TABLE 84 Key Information – Amgen, Inc.
TABLE 85 Key Information – Novartis AG
TABLE 86 Key Information – Sorrento Therapeutics, Inc.
TABLE 87 Key Information – Bristol Myers Squibb Company
TABLE 88 Key Information – Pfizer, Inc.
TABLE 89 Key Information – Immunocore Holdings plc
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Sep – 2023, May) Leading Players
FIG 5 North America T-Cell therapy Market share by End User, 2022
FIG 6 North America T-Cell therapy Market share by End User, 2030
FIG 7 North America T-Cell therapy Market by End User, 2019 - 2030, USD Million
FIG 8 North America T-Cell therapy Market share by Indication, 2022
FIG 9 North America T-Cell therapy Market share by Indication, 2030
FIG 10 North America T-Cell therapy Market by Indication, 2019 - 2030, USD Million
FIG 11 North America T-Cell therapy Market share by Therapy Type, 2022
FIG 12 North America T-Cell therapy Market share by Therapy Type, 2030
FIG 13 North America T-Cell therapy Market by Therapy Type, 2019 - 2030, USD Million
FIG 14 North America T-Cell therapy Market share by Country, 2022
FIG 15 North America T-Cell therapy Market share by Country, 2030
FIG 16 North America T-Cell therapy Market by Country, 2019 - 2030, USD Million
FIG 17 Recent strategies and developments: Merck KGaA
FIG 18 Recent strategies and developments: Johnson & Johnson
FIG 19 SWOT analysis: Johnson & Johnson
FIG 20 Recent strategies and developments: Gilead Sciences, Inc.
FIG 21 Recent strategies and developments: Amgen, Inc.
FIG 22 Recent strategies and developments: Novartis AG
FIG 23 Recent strategies and developments: Sorrento Therapeutics, Inc.
FIG 24 Recent strategies and developments: Bristol Myers Squibb Company
FIG 25 Recent strategies and developments: Pfizer, Inc.
FIG 26 Recent strategies and developments: Immunocore Holdings plc